Navigation Links
Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
Date:11/28/2007

cers and pressure sores.

The '648 patent describes a novel, fully biodegradable and resorbable collagen-based material with improved mechanical, physical and functional properties that has application as a wound covering or surgical implant for the purpose of tissue augmentation and repair where mechanical strength is especially desirable. The material may optionally contain drugs and other bioactive substances for local delivery to the site of implantation or tissue defect.

Commenting on receipt of the notices, Dr. Michael Myers, President and CEO said, "The grant of these two patents will both broaden and strengthen the intellectual property covering our core CollaRx platform technology and particularly its applications in wound healing, biosurgery and local drug delivery. Having now secured both European and US patent rights for our advanced wound care product, DermaSIL, we are intent on scaling-up the proprietary manufacturing process and commercializing this product in 2008 through our CollMED Laboratories joint venture in the US and in collaboration with distribution partners in Europe."

About CollaRx(R)

CollaRx is Innocoll's lead technology platform for the site specific, local delivery of a wide variety of drugs with particular emphasis on antibiotics, anesthetics, anti-cancer agents and tissue regeneration proteins and peptides. The CollaRx technology forms the basis of Innocoll's lead product, Gentamicin Surgical Implant, a biodegradable leave-behind implant indicated for the treatment and prevention of surgical site infection in both hard and soft tissue. This product is already approved in 49 countries and is in phase 3 development in the US. Other CollaRx sponge products under clinical development by Innocoll include a CollaRx Bupivacaine Implant for the management of post-operative pain and a topically-applied CollaRx Gentamicin Sponge for the treatment and prevention of diabetic foot infections. Innocoll's CollaRx membrane
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
10. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... , ... A scar is an unavoidable result of incision or injury to the skin. Unsightly ... heal itself. The appearance of a scar is dependent on many factors – the size ... ”Many scars fade to near invisibility on their own over a period of months,” says ...
(Date:9/3/2015)... ... September 03, 2015 , ... The new ... Report of Provo, Utah. The Clinicians Report is a leading information source to ... located throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated for ...
(Date:9/3/2015)... ... September 03, 2015 , ... James Earl Jones will be hosting an upcoming ... James Earl Jones will introduce a segment that discusses why it is important for ... wellness can be fostered in any working environment. , Employers are out billions of ...
(Date:9/2/2015)... ... ... The Aspen Clinic (TAC), located in Basalt, Colorado, today announced ... wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director of ... fitness - we are much more than a gym. Our fitness and wellness ...
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system introduces ... of the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or two ... any given guide RNA (sgRNA or crRNA) to create a break in the target ...
Breaking Medicine News(10 mins):Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4
... Financial Options Guide Now Available at Sunrise Communities and ... (NYSE: SRZ ) now offers a new ... ideas for affording senior care in today,s challenging economy. ... Financial Options , is available at Sunrise communities nationwide ...
... to be a first-ever procedure, surgeons at Johns Hopkins ... small incision in the back of the donor,s vagina. ... the donor,s niece, and both patients are doing fine," ... division at Johns Hopkins University School of Medicine who ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... call with simultaneous webcast on Tuesday, February 3, 2009 ... of Rigel,s senior management team will provide an update ... and Webcast Information To access the live call, please ...
... EPS Despite a Challenging Economic Environment BEDFORD, Mass., Feb. 2 ... HOLX ), a leading developer, manufacturer and supplier of premium ... the healthcare needs of women, today announced its results for ... quarter include: , ...
... common minimally invasive biopsy method used in the US, ... 14-gauge needle decreasing a physician,s chances of false-negative diagnoses, ... School of Medicine in Stanford, CA. , The ... using a 14-gauge or 11-gauge vacuum needle. Results showed ...
... February 02, 2009 The antiepileptic drug vigabatrin (VGB) has ... a special form of epilepsy in infants, called infantile spasm. ... it has been shown to cause a permanent narrowing of ... been exposed at school age or later. A new study ...
Cached Medicine News:Health News:Sunrise Senior Living Helps Families Explore Senior Care Financing Options with New Guide 2Health News:Hopkins transplant surgeons remove healthy kidney through donor's vagina 2Health News:Rigel to Host Conference Call on February 3, 2009 2Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 2Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 3Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 4Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 5Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 6Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 7Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 8Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 9Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 10Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 11Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 12Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 13Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 14Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 15Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 16Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 17Health News:Controversial medication may decrease spasms for infants with epilepsy 2
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has ... China (Basel, Switzerland - November 26-27, 2015)" conference to ... detailed overview of the key areas of pharmaceutical regulatory affairs ... , Macau and ... All important aspects of gaining and maintaining a successful Marketing ...
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has announced ... (London, UK - November 16-17, 2015)" conference to ... modules concerning Pharmacovigilance are a major departure in terms ... Europe . The intention of the course is ... how they overlap and fit together and what Companies ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... NEW YORK, Jan. 13, 2011 Reportlinker.com announces ... in its catalogue: H. Lundbeck ... Introduction ... for Lundbeck in the prescription pharmaceutical sector. The ...
... 13, 2011 Reportlinker.com announces that a new ... Merck & Co., Inc.: PharmaVitae ... IntroductionThis analysis examines the historical and ... prescription pharmaceutical sector. The profile encompasses global company ...
Cached Medicine Technology:Reportlinker Adds H. Lundbeck A/S: PharmaVitae Profile 2Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: